TJ242B - A method of treatment an ovarian estrogen dependent condition - Google Patents

A method of treatment an ovarian estrogen dependent condition

Info

Publication number
TJ242B
TJ242B TJ96000402A TJ96000402A TJ242B TJ 242 B TJ242 B TJ 242B TJ 96000402 A TJ96000402 A TJ 96000402A TJ 96000402 A TJ96000402 A TJ 96000402A TJ 242 B TJ242 B TJ 242B
Authority
TJ
Tajikistan
Prior art keywords
dependent condition
treatment
estrogen dependent
ovarian estrogen
administration
Prior art date
Application number
TJ96000402A
Other languages
English (en)
Inventor
Gary D Hodger
Robert F Willaims
Daniel Grow
Original Assignee
Hampton Roads Medical College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hampton Roads Medical College filed Critical Hampton Roads Medical College
Publication of TJ242B publication Critical patent/TJ242B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TJ96000402A 1994-02-04 1995-02-02 A method of treatment an ovarian estrogen dependent condition TJ242B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/191,631 US5681817A (en) 1994-02-04 1994-02-04 Treatment of ovarian estrogen dependent conditions
PCT/US1995/001479 WO1995020972A1 (en) 1994-02-04 1995-02-02 Treatment of ovarian estrogen dependent conditions

Publications (1)

Publication Number Publication Date
TJ242B true TJ242B (en) 1999-11-24

Family

ID=22706258

Family Applications (1)

Application Number Title Priority Date Filing Date
TJ96000402A TJ242B (en) 1994-02-04 1995-02-02 A method of treatment an ovarian estrogen dependent condition

Country Status (29)

Country Link
US (1) US5681817A (show.php)
EP (1) EP0785792B1 (show.php)
JP (1) JP3130048B2 (show.php)
KR (1) KR970700507A (show.php)
CN (1) CN1144486A (show.php)
AP (1) AP724A (show.php)
AT (1) ATE179610T1 (show.php)
AU (1) AU689229B2 (show.php)
BG (1) BG62238B1 (show.php)
BR (1) BR9506606A (show.php)
CA (1) CA2182183C (show.php)
CZ (1) CZ291709B6 (show.php)
DE (1) DE69509544T2 (show.php)
DK (1) DK0785792T3 (show.php)
ES (1) ES2132645T3 (show.php)
FI (1) FI963036L (show.php)
GR (1) GR3030164T3 (show.php)
HU (1) HUT74622A (show.php)
LT (1) LT4182B (show.php)
LV (1) LV11782B (show.php)
MD (1) MD1432C2 (show.php)
NZ (1) NZ281441A (show.php)
OA (1) OA10777A (show.php)
PL (1) PL178273B1 (show.php)
RO (1) RO117420B1 (show.php)
RU (1) RU2110274C1 (show.php)
SK (1) SK96296A3 (show.php)
TJ (1) TJ242B (show.php)
WO (1) WO1995020972A1 (show.php)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996003138A1 (en) * 1994-07-22 1996-02-08 The Medical College Of Hampton Roads Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens
US5780435A (en) * 1995-12-15 1998-07-14 Praecis Pharmaceuticals Incorporated Methods for treating prostate cancer with LHRH-R antagonists
US6274573B1 (en) 1997-10-17 2001-08-14 Mochida Pharmaceutical Co., Ltd. Method of treatment for uterine leiomyoma
US6703367B1 (en) 1999-04-27 2004-03-09 Praecis Pharmaceuticals Inc. Methods for treating hot flashes and gynaecomastia
US6399593B1 (en) 1999-05-04 2002-06-04 Wyeth Cyclic regimens using cyclic urea and cyclic amide derivatives
US6444668B1 (en) 1999-05-04 2002-09-03 Wyeth Combination regimens using progesterone receptor modulators
US6358948B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
US6462032B1 (en) 1999-05-04 2002-10-08 Wyeth Cyclic regimens utilizing indoline derivatives
US6329416B1 (en) 1999-05-04 2001-12-11 American Home Products Corporation Combination regimens using 3,3-substituted indoline derivatives
US6391907B1 (en) * 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
US6306851B1 (en) 1999-05-04 2001-10-23 American Home Products Corporation Cyclocarbamate and cyclic amide derivatives
US6407101B1 (en) 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
US6380178B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Cyclic regimens using cyclocarbamate and cyclic amide derivatives
US6319912B1 (en) 1999-05-04 2001-11-20 American Home Products Corporation Cyclic regimens using 2,1-benzisothiazoline 2,2-dioxides
US6369056B1 (en) 1999-05-04 2002-04-09 American Home Products Corporation Cyclic urea and cyclic amide derivatives
US6339098B1 (en) 1999-05-04 2002-01-15 American Home Products Corporation 2,1-benzisothiazoline 2,2-dioxides
US6355648B1 (en) * 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
US6358947B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Tetracyclic progesterone receptor modulator compounds and methods
US6417214B1 (en) 1999-05-04 2002-07-09 Wyeth 3,3-substituted indoline derivatives
US6498154B1 (en) 1999-05-04 2002-12-24 Wyeth Cyclic regimens using quinazolinone and benzoxazine derivatives
US6423699B1 (en) 1999-05-04 2002-07-23 American Home Products Corporation Combination therapies using benzimidazolones
US6509334B1 (en) 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
US6380235B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Benzimidazolones and analogues
US8193252B1 (en) 1999-08-31 2012-06-05 Bayer Pharma AG Mesoprogestins (progesterone receptor modulators) for the treatment and prevention of benign hormone dependent gynecological disorders
ES2295050T3 (es) * 1999-08-31 2008-04-16 Bayer Schering Pharma Aktiengesellschaft Mesoprogestinas para el tratamiento y la prevencion de trastornos ginecologicos benignos dependientes de hormonas.
UA73119C2 (en) * 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
AU2001295359A1 (en) * 2000-10-30 2002-05-15 University Of Zurich GnRH analogues for treatment of urinary incontinence
US6958142B2 (en) * 2002-08-02 2005-10-25 Balance Pharmaceuticals, Inc. Nasal spray formulation and method
US6960337B2 (en) * 2002-08-02 2005-11-01 Balance Pharmaceuticals, Inc. Methods and compositions for treating benign gynecological disorders
US7029657B2 (en) * 2002-08-02 2006-04-18 Balance Pharmaceuticals, Inc. Nasal spray steroid formulation and method
GB0302572D0 (en) 2003-02-05 2003-03-12 Astrazeneca Ab Method of treatment
EP1865935B1 (en) * 2005-02-17 2011-06-08 Hadasit Medical Research Services and Development Ltd. Bisphosphonates for treating endometriosis
US20060251581A1 (en) * 2005-05-09 2006-11-09 Mcintyre Jon T Method for treatment of uterine fibroid tumors
US7862552B2 (en) 2005-05-09 2011-01-04 Boston Scientific Scimed, Inc. Medical devices for treating urological and uterine conditions
TWI455716B (zh) * 2006-10-24 2014-10-11 Repros Therapeutics Inc 選擇性黃體激素受體調節劑用於製造治療雌激素依賴性病症之藥物的用途
MY150763A (en) * 2006-10-24 2014-02-28 Repros Therapeutics Inc Compositions and methods for suppressing endometrial proliferation
WO2008144143A1 (en) * 2007-05-14 2008-11-27 Drugtech Corporation Endometriosis treatment
US20110208118A1 (en) * 2007-09-20 2011-08-25 Bio-Pro Medical Ltd. Compositions and means for treating uterine leiomyomata, leiomyoma, myoma, uterine fibroids, endometriosis, adenomyosis and related disorders by mifepristone
RU2359684C1 (ru) * 2008-01-23 2009-06-27 Закрытое акционерное общество "СКАЙ ЛТД" Способ лечения эндометриоза
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
EP3560555A1 (en) 2018-04-26 2019-10-30 LifeArc A composition for treating one or more estrogen related diseases

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA8231B (en) 1981-01-09 1982-11-24 Roussel Uclaf New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained
US4780461A (en) 1983-06-15 1988-10-25 Schering Aktiengesellschaft 13α-alkyl-gonanes, their production, and pharmaceutical preparations containing same
DE3347126A1 (de) 1983-12-22 1985-07-11 Schering AG, 1000 Berlin und 4709 Bergkamen 11ss-aryl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
DE19975054I2 (de) 1987-08-08 2000-04-13 Akzo Nobel Nv Kontrazeptives Implantat
DE3744054A1 (de) 1987-12-21 1989-06-29 Schering Ag Verwendung von antigestagenen zur herstellung von arzneimitteln
DE3921059A1 (de) 1989-06-23 1991-01-10 Schering Ag 11(beta)-aryl-4-estrene, verfahren zu ihrer herstellung sowie deren verwendung als arzneimittel
EP0472725B1 (en) 1990-03-16 1997-05-21 Applied Research Systems Ars Holding N.V. Treatment of polycystic ovarian disease
US6827050B2 (en) 2001-12-21 2004-12-07 Caterpillar Inc Fluid control valve actuating system
US7283632B2 (en) 2003-09-09 2007-10-16 The Boeing Company Unauthorized access embedded software protection system

Also Published As

Publication number Publication date
BR9506606A (pt) 1997-09-09
CN1144486A (zh) 1997-03-05
LV11782A (lv) 1997-06-20
FI963036A0 (fi) 1996-08-01
FI963036A7 (fi) 1996-08-01
ES2132645T3 (es) 1999-08-16
SK96296A3 (en) 1997-07-09
OA10777A (en) 2002-12-23
MD1432C2 (ro) 2000-09-30
AU689229B2 (en) 1998-03-26
LT4182B (en) 1997-06-25
DE69509544D1 (de) 1999-06-10
DK0785792T3 (da) 1999-10-18
EP0785792B1 (en) 1999-05-06
DE69509544T2 (de) 1999-09-02
RO117420B1 (ro) 2002-03-29
BG62238B1 (bg) 1999-06-30
PL178273B1 (pl) 2000-03-31
BG100766A (bg) 1997-06-30
GR3030164T3 (en) 1999-08-31
MD1432B2 (en) 2000-03-31
CA2182183C (en) 2003-09-16
WO1995020972A1 (en) 1995-08-10
AP9600840A0 (en) 1996-07-31
EP0785792A4 (show.php) 1997-07-30
CA2182183A1 (en) 1995-08-10
US5681817A (en) 1997-10-28
CZ291709B6 (cs) 2003-05-14
EP0785792A1 (en) 1997-07-30
JPH09508418A (ja) 1997-08-26
FI963036L (fi) 1996-08-01
NZ281441A (en) 1999-09-29
RU2110274C1 (ru) 1998-05-10
ATE179610T1 (de) 1999-05-15
LT96133A (en) 1997-01-27
LV11782B (en) 1997-12-20
AU1838695A (en) 1995-08-21
CZ210396A3 (en) 1997-05-14
JP3130048B2 (ja) 2001-01-31
PL315792A1 (en) 1996-12-09
AP724A (en) 1999-01-18
KR970700507A (ko) 1997-02-12
HUT74622A (en) 1997-01-28
HU9601969D0 (en) 1996-09-30

Similar Documents

Publication Publication Date Title
HU9601969D0 (en) Treatment of ovarian estrogen dependent conditions
IL124459A0 (en) Antagonists of gonadotropin releasing hormone
MX9804850A (es) Antagonistas de hormona liberadora de gonadotropina.
NZ325060A (en) Non peptide indole derivative and their use as antagonists of gonadotropin releasing hormone
DE69511379D1 (en) Immunogens gegen gonadotropin releasing hormone
TW366342B (en) The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
PL327182A1 (en) Method of preventing conception among female mammals through combined application of gestagen and oestrogen and combination of active agent therefor
PH30177A (en) Sulfonate derivatives of 3-aroylbenzo(b) thiophenes
FI970260L (fi) Progesteroniantagonisti ja gestageeni endometrioosin ja leiomyomata uterin hoitamiseksi
NZ323456A (en) Pharmaceutical composition of an estrogen agonist/antagonist and a prostaglandin or a prostaglandin agonist/antagonist; useful for combination therapy for osteoporosis
DE69710896D1 (en) Progestogen-anti-progestogen therapien
UA37259C2 (uk) Активна речовина для одержання лікарських засобів при лікуванні дисфункціональних маткових кровотеч
NO20005145L (no) FremgangsmÕte for behandling av fertilitetsproblemer
CA2137595A1 (en) Treating hormone-dependent conditions
NO985573L (no) Veksthormonkomponent og ben-antiresorpsjonsmiddel ved syklisk (koherens-) behandling av osteoporose
WO2000021511A3 (en) Subcutaneous medroxyprogesterone acetate for treatment of menopause and endometriosis
CA2248841A1 (en) Sequential oestrogen/progesterone antagonist combination for hormone replacement therapy
UA29349A (uk) Спосіб лікування ановуляторної неплідності
GB2369574A (en) Initiation of oestrus
UA29965A (uk) Спосіб моделювання гострих виразок шлунка
GEP19991860B (en) Method for Treatment of Ovarian Estrogen Dependent Conditions
MX9701531A (es) Terapia de combinacion para tratar la osteoporosis-polifosfonatos o progestinas y agonistas de estrogenos.
MX9702207A (es) Combinacion de prostaciclina con un estrogeno o progestina para la prevencion y tratamiento de enfermedades ateroescleroticas vasculares incluyendo preclampsia y para el tratamiento de hipertension y para terapia de reeplazo de hormonas.